Administer intravenously as a bolus injection followed by continuous intravenous infusion. It should be administered via a dedicated IV line or through an existing IV line with no other medications.

Eptifibatide reversibly binds to the platelet glycoprotein IIb/IIIa receptor, preventing the binding of fibrinogen, von Willebrand factor, and other adhesive ligands. This inhibits platelet aggregation and thrombus formation.

• •Active pathological bleeding (e.g., gastrointestinal bleeding, intracranial hemorrhage) within 30 days.
• •History of stroke within 30 days or any history of hemorrhagic stroke.
• •Major surgery or severe trauma within 6 weeks.
• •Severe uncontrolled hypertension (systolic > 200 mmHg or diastolic > 110 mmHg).
• •History of thrombocytopenia following previous administration of Eptifibatide.
• •Serum creatinine ≥ 4.0 mg/dL.
• •Concomitant use of another glycoprotein IIb/IIIa inhibitor.

Store refrigerated at 2-8°C (36-46°F). Do not freeze. Protect from light. May be stored at room temperature (20-25°C or 68-77°F) for up to 2 months if protected from light.

Overdose primarily increases the risk of bleeding. Management involves discontinuing Eptifibatide and other antithrombotic agents, careful clinical monitoring, and appropriate treatment of bleeding. Platelet transfusions may be considered in severe cases.

Pregnancy Category B. Studies in animals have shown no evidence of fetal harm, but there are no adequate and well-controlled studies in pregnant women. Use only if clearly needed. It is not known whether Eptifibatide is excreted in human milk; caution should be exercised when administered to a nursing mother.